InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc

Bullboard Posts

Post by BeeInveSTINGon Apr 18, 2019 8:27pm

185 Views

Post# 29647649

Biosynthetic Cannabinoid Conference Review. MIDAS LETTER

Here are some thoughts from James West and Alan Brochstein, whom attended the conference. I was a little discouraged to hear about the suggested negative views surrounding the E.coli chassis and InMed. One must take into account also that this is an ever emerging field, and whilst InMed was not presenting at the conference... their competitors were. https://www.youtube.com/watch?v=bULUI7ET4AE

Bullboard Posts

Junior helium stock to benefit from new legislation in U.S.